Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study Study conducted at The Massachusetts General Hospital’s [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor  Seasoned Clinician, Developer and Health System Leader to provide expertise and guidance [...]

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology  Study is designed to assess immunologic responses, efficacy and safety of a novel self-assembling vaccine candidate  Data [...]

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company, Announces Industry Veteran Dr. Simon Pedder has Joined the Board of Directors  Seasoned product development expert to provide leadership on development of the Voltron’s Self [...]

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company Announces Selection of Therapeutic Targets for Immuno-Oncology Program Targets selected to target a wide range of important cancers  Voltron Therapeutics, Inc, a [...]

Voltron Therapeutics, Inc.’s Scientific Co-Founder Dr. Mark C. Poznansky has Guest Essay Published in the New York Times  “The Vaccines We Have Are Good. But They Could Be So Much Better” [...]